What Shapes Malpractice Coverage? By Erik Leander Richard Anderson This video explains how the Medical Injury Compensation Reform Act has shaped malpractice coverage.
AI: The Next Stage in Healthcare By Stephen Ambrose Many medical professionals fear that AI will cost them their jobs, but costs must somehow decline, and errors must plunge.
Gene Testing: Time Is Ripe in Work Comp By Nancy Grover Gene testing is showing promise as a tool to get the right medication at the right dose to each workers' compensation patient.
#1 Affliction Costing Businesses Billions By Craig Lack Healthcare is "managed" as a large operational expense — instead of as a strategic asset that delivers a sustainable competitive advantage.
7 Reasons to Invest in Medical Analytics By Karen Wolfe As many other industries have shown, being analytics-poor in workers' comp is no longer an option.
Opioids Are the Opiates of the Masses By Al Lewis Employers can help head off chronic use of opioids before it turns into addiction by having independent analysis look for three key risk factors.
The Case Against Whole Life Policies By Tony Steuer Forty years ago, whole life insurance made a lot of sense as an investment vehicle. Today, it's as outdated as disco, hula hoops and pet rocks.
Healthcare Case on Cutting Corners By Cynthia Marcotte Stamer A settlement with Raleigh Orthopaedic is just the latest in a growing series of high-dollar resolution agreements about privacy standards.
Auto Insurance in an Existential Crisis By Stephen Applebaum Alan Demers The 125-year-old, $300 billion U.S. auto insurance industry is caught between runaway inflation and strained consumer wallets.
The Promise of Continuous Underwriting By Bill Deemer Bobby Touran Typically, a risk is underwritten, bound... and forgotten. But new streams of data and automation allow for continuous underwriting.
Convergence and the Insurance Ecosystem By Stephen Applebaum Alan Demers Companies must anticipate the future, innovate beyond their core and transform their capabilities as rapidly as technology allows.
Lemonade's 'Synthetic Agent' Nonsense By Matteo Carbone Desperate for growth, Lemonade produces another howler: A lender receiving a 16% interest rate is presented as a (synthetic) agent.